Staidson (Beijing) BioPharmaceuticals (SHE:300204) released the preliminary results for clinical trials for a drug that will treat patients with acute respiratory distress syndrome or ARDS, according to a Shenzhen bourse filing on Wednesday.
The Phase Ib/II clinical trials, which evaluates the safety and efficiency of the STSA-1002 injection, found that the drug showed mortality reductions of 33% and 85% for the low-dose and high-dose groups, respectively. The drug also showed clinical improvement rates of more than 70% for both groups.
The clinical trials received approval from the Chinese drug administration in March, the biopharmaceutical company said.
Staidson Bio's shares surged 20% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.